Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 18/20 | 0.61 |
| ▸ | NAMPT | P43490 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17452601 | 0.86 | ROCK2 (0.57) | ROCK2NAMPTPOLBROCK1NPC1 | |
| SCHEMBL19902337 | 0.82 | NPC1 (0.57) | ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL19902318 | 0.82 | ROCK1 (0.55) | ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL19902689 | 0.81 | ROCK2 (0.46) | ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL19902590 | 0.80 | ROCK2 (0.53) | ROCK2NAMPTROCK1NPC1RAB9A | |
| SCHEMBL19902449 | 0.78 | ROCK1 (0.59) | ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL19902690 | 0.78 | SMN1; SMN2 (0.44) | ROCK2POLBROCK1NPC1RAB9A | |
| SCHEMBL17452547 | 0.78 | ROCK2 (0.51) | ROCK2NAMPTROCK1 | |
| SCHEMBL19902473 | 0.78 | NPC1 (0.46) | ROCK2ROCK1NPC1RAB9A | |
| SCHEMBL1789261 | 0.78 | ATM (0.50) | ROCK2POLBROCK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | ROCK2 3/4885NAMPT 2376/4885POLB 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.